Multi-treatment optimal response-adaptive designs for phase III clinical trials
From MaRDI portal
Publication:744587
DOI10.1016/J.JKSS.2010.04.004zbMATH Open1296.62155OpenAlexW1987072912MaRDI QIDQ744587FDOQ744587
Atanu Biswas, Saumen Mandal, Rahul Bhattacharya
Publication date: 25 September 2014
Published in: Journal of the Korean Statistical Society (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.jkss.2010.04.004
Recommendations
- Intermediate Monitoring, Sample Size Reassessment, and Multi-Treatment Optimal Response-Adaptive Designs for Phase III Clinical Trials with More Than One Constraint
- Optimal response-adaptive allocation designs in phase III clinical trials: incorporating ethics in optimality
- Optimal response-adaptive designs for continuous responses in phase III trials
- An optimal response-adaptive design with dual constraints
- A new response-adaptive design for continuous treatment responses for phase III clinical trials
Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Sequential statistical design (62L05)
Cites Work
- The Randomized Play-the-Winner Rule in Medical Trials
- Title not available (Why is that?)
- Asymptotic inference with response-adaptive treatment allocation designs
- Title not available (Why is that?)
- Title not available (Why is that?)
- Bayesian Adaptive Biased‐Coin Designs for Clinical Trials with Normal Responses
- The generalized Polya's urn design for sequential medical trials
- A birth and death urn for randomized clinical trials: asymptotic methods
- A sequential design for maximizing the probability of a favourable response
- A play-the-winner-type urn design with reduced variability
- Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials.
- Response-adaptive designs for continuous outcomes
- Adaptive designs for normal responses with prognostic factors
- Optimality, Variability, Power
- Implementing Optimal Allocation in Sequential Binary Response Experiments
- Response‐Adaptive Randomization for Clinical Trials with Continuous Outcomes
- Inference for a RPW-Type Clinical Trial with Repeated Monitoring for the Treatment of Rheumatoid Arthritis
- Optimal Response‐Adaptive Designs for Normal Responses
- Implementing optimal allocation for sequential continuous responses with multiple treatments
- An adaptive allocation for continuous response using Wilcoxon-Mann-Whitney score
- Sequential Estimation of a Linear Function of Means of Three Normal Populations
- Optimal Response‐Adaptive Designs for Continuous Responses in Phase III Trials
Cited In (16)
- On Multi-Treatment Adaptive Allocation Design for Dichotomous Response
- Adaptive two‐treatment two‐period crossover design for binary treatment responses
- On optimal designs for clinical trials: an updated review
- Implementing unequal randomization in clinical trials with heterogeneous treatment costs
- Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets
- Optimal and ethical designs for hypothesis testing in multi-arm exponential trials
- On recent advances in optimal allocation designs in clinical trials
- Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress
- Benefit–Risk Evaluation of Multi-Stage Adaptive Designs
- Multi-arm response-adaptive designs for circular responses
- Title not available (Why is that?)
- Intermediate Monitoring, Sample Size Reassessment, and Multi-Treatment Optimal Response-Adaptive Designs for Phase III Clinical Trials with More Than One Constraint
- Sequential monitoring of response-adaptive randomized clinical trials with sample size re-estimation
- Adaptive Designs to Maximize Power in Clinical Trials with Multiple Treatments
- Group-sequential response-adaptive designs for multi-armed trials
- Optimal adaptive generalized Pólya urn design for multi-arm clinical trials
This page was built for publication: Multi-treatment optimal response-adaptive designs for phase III clinical trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q744587)
